Each Zerifax tablet contains 200 mg or 550 mg of rifaximin
Zerifax tablet contain rifaximin, a non-aminoglycoside semi-synthetic, nonsystemic antibiotic derived from rifamycin. Rifaximin is a structural analog of rifampin
ZERIFAX 200 mg is indicated for the treatment of patients (≥ 12 years of age) with travelers’ diarrhea caused by noninvasive strains of Escherichia coli.
Limitations of Use: ZERIFAX should not be used in patients with diarrhea complicated by fever or blood in the stool or diarrhea due to pathogens other han Escherichiacoli.
Irritable Bowel Syndrome with Diarrhea: ZERIFAX is indicated for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.
Hepatic Encephalopathy: Zerifax 550 mg is indicated for reduction in risk of overt hepatic encephalopathy (HE) recurrence in patients 18 years of age.
Dosage for Travelers’ Diarrhea:
The recommended dose of ZERIFAX is one 200 mg tablet taken orally three times a day for 3 days. ZERIFAX can be administered orally, with or without food.
Dosage for Irritable Bowel Syndrome with Diarrhea: The recommended dose of ZERIFAX is one 550 mg tablet taken orally three times a day for 14 days. Patients who experience a recurrence of symptoms can be retreated up to two times with the same dosage regimen.
Dosage for Hepatic Encephalopathy:
The recommended dose of Zerifax is one 550 mg tablet taken orally two times a day, with or without food.